Trials / Recruiting
RecruitingNCT06335914
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Ga 68 PSMA-11 PET | Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer |
| DIAGNOSTIC_TEST | 18F-DCFPyL PET | Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer. |
| DIAGNOSTIC_TEST | FDG PET | Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer. |
Timeline
- Start date
- 2025-04-03
- Primary completion
- 2029-03-04
- Completion
- 2029-09-04
- First posted
- 2024-03-28
- Last updated
- 2026-02-12
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06335914. Inclusion in this directory is not an endorsement.